Sign in

LKFT on Nasdaq

Galápagos NV

Logo: Galapagos N.V., Public domain, via Wikimedia Commons5

Belgian pharmaceutical research company

Lakefront Biotherapeutics (formerly known as Galapagos NV and Galapagos Genomics) is a Belgian pharmaceutical research company which was founded in 1999. Its headquarters are located in Mechelen and has additional locations in Leiden, Romainville, Basel, Milan, Madrid, Boston and Zagreb. The company develops drugs against rheumatoid arthritis, Crohn's disease, ulcerative colitis, psoriasis, systemic lupus erythematosus and cystic fibrosis.3 It was founded by Onno van de Stolpe.1 Its shares trade on Nasdaq under the symbol LKFT.1 Wikipedia text CC BY-SA 4.0

Price unavailable

Last updated Oct 21, 2026.

Overview

1.1BRevenue, fiscal 20256
320.9MNet income, fiscal 20256
1999Founded1

Compare with Evotec, Ascendis Pharma A/S or Morphosys, or pick any stock.

  • TickerLKFT on Nasdaq1
  • Industrypharmaceutical industry1
  • HeadquartersMechelen1
  • Websitewww.glpg.com
  • Legal formPublic limited company (Belgium)1
  • Listed onAmsterdam Stock Exchange (GLPG), Nasdaq (GLPG)1
  • Incorporated inBelgium7
  • Business addressSchalienhoevedreef 20T, 2800 Mechelen7
  • Filer categoryLarge accelerated filer7
  • LEI549300QKJ78IY0IOV6554
  • StatusActive4
  • LEI statusIssued and current4
  • Registered addressSchaliënhoevedreef 20T, 2800 Mechelen, Belgium4
  • Registered withFederal Public Service Economy (Ministry of Economy), 0466.460.4294

See how the biggest companies compare on our leaderboards

Darwinweg 24 Leiden
Photo: Bic, CC BY-SA 4.0, via Wikimedia Commons9

Lakefront Biotherapeutics (formerly known as Galapagos NV and Galapagos Genomics) is a Belgian pharmaceutical research company which was founded in 1999. Its headquarters are located in Mechelen and has additional locations in Leiden, Romainville, Basel, Milan, Madrid, Boston and Zagreb.3

Financials

From the company’s reports to the SEC. Every number links to the filing it came from. Figures are in EUR, the currency the company reports in.

Key numbers, fiscal 2025

26.5%Operating margin6
28.9%Net margin6
303.5%Revenue growth, 20256
9.9%Return on equity6
-271.2M EURFree cash flow6

Where the money goes

Where each dollar of revenue went, fiscal 2025

  • Cost of revenue3¢29.7M EUR
  • Research and development41¢459.4M EUR
  • Other costs25¢282.6M EUR
  • Interest0¢1.0M EUR
  • Income tax2¢18.6M EUR
  • Profit29¢320.9M EUR

Out of 1.1B EUR in revenue.6

Financial statements

Revenue101112131461.1B EUR in 2025+299% since 2018
0500.0M EUR1.0B EUR1.5B EUR2018: 278.7M EUR278.7M EUR20182019: 834.9M EUR834.9M EUR2019+200%2020: 478.1M EUR478.1M EUR2020−43%2021: 234.4M EUR234.4M EUR2021−51%2022: 241.2M EUR241.2M EUR2022+3%2023: 239.7M EUR239.7M EUR2023−1%2024: 275.6M EUR275.6M EUR2024+15%2025: 1.1B EUR1.1B EUR2025+304%
Operating income10111213146295.0M EUR in 2025
-200.0M EUR0200.0M EUR400.0M EUR2018: -47.1M EUR-47.1M EUR20182019: 368.7M EUR368.7M EUR20192020: -178.6M EUR-178.6M EUR20202021: -171.6M EUR-171.6M EUR2021−4%2022: -131.1M EUR-131.1M EUR2022−24%2023: -88.3M EUR-88.3M EUR2023−33%2024: -188.3M EUR-188.3M EUR2024+113%2025: 295.0M EUR295.0M EUR2025
Net income10111213146320.9M EUR in 2025
-400.0M EUR-200.0M EUR0200.0M EUR400.0M EUR2018: -29.3M EUR-29.3M EUR20182019: 149.8M EUR149.8M EUR20192020: -305.4M EUR-305.4M EUR20202021: -103.2M EUR-103.2M EUR2021−66%2022: -218.0M EUR-218.0M EUR2022+111%2023: 211.7M EUR211.7M EUR20232024: 74.1M EUR74.1M EUR2024−65%2025: 320.9M EUR320.9M EUR2025+333%

Every line of the income statement as filed: the last 3 fiscal years, latest first.6

Period ending2025-12-312024-12-312023-12-31
Supply revenues29.9M EUR34.9M EUR
Collaboration revenues1.1B EUR240.8M EUR239.7M EUR
Total net revenues1.1B EUR275.6M EUR239.7M EUR
Cost of sales-29.7M EUR-34.9M EUR
Research and development expenses-459.4M EUR-335.5M EUR-241.3M EUR
Sales and marketing expenses-6.1M EUR-17.2M EUR-5.7M EUR
General and administrative expenses-147.3M EUR-117.2M EUR-128.3M EUR
Impairment of the cell therapy business-228.1M EUR
Other operating income53.5M EUR40.8M EUR47.3M EUR
Operating loss295.0M EUR-188.3M EUR-88.3M EUR
Fair value adjustments and net exchange differences-39.4M EUR95.8M EUR16.3M EUR
Other financial income48.1M EUR91.1M EUR80.2M EUR
Other financial expenses-2.9M EUR-1.7M EUR-2.6M EUR
Profit / (Loss) (-) before tax300.9M EUR-3.1M EUR5.6M EUR
Income taxes18.6M EUR1.8M EUR-9.6M EUR
Net loss from continuing operations319.5M EUR-1.3M EUR-4.0M EUR
Net profit/(loss) (-) from discontinued operations, net of tax1.4M EUR75.4M EUR215.7M EUR
Net profit / (loss) (-)320.9M EUR74.1M EUR211.7M EUR
Owners of the parent320.9M EUR74.1M EUR211.7M EUR
Basic earnings per share (in EUR per share)4.87 EUR1.12 EUR3.21 EUR
Diluted earnings per share (in EUR per share).4.87 EUR1.12 EUR3.21 EUR
Basic and diluted loss per share from continuing operations (in EUR per share)4.85 EUR-0.02 EUR-0.06 EUR
Basic and Diluted loss per share from continuing operations (in EUR per share).4.85 EUR-0.02 EUR-0.06 EUR
Weighted average number of shares - Basic (in '000 shares)65.9M shares65.9M shares65.9M shares
Weighted average number of shares - Diluted (in '000 shares)65.9M shares65.9M shares65.9M shares

Compare Galápagos NV with another company

Corporate structure

Galápagos NV sits at the top of its group. 4 entities, 3 countries on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Galápagos NV

  • Galápagos NV Mechelen, Belgium
    • Galapagos (France) Subsidiary
    • Galapagos Cell Therapeutics Subsidiary · Mechelen, Belgium
    • Galápagos NV (Croatia) Subsidiary · Croatia

Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); subsidiaries, stakes and holdings from Wikidata (CC0); major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Galápagos NV reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, net71.9M EUR6 Dec 31, 2025105.4M EUR6 Dec 31, 2024−31.7%
Operating-lease assets (leased space)8.7M EUR6 Dec 31, 202517.5M EUR6 Dec 31, 2024−50.2%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$40.0M6 Dec 31, 2025$40.3M14 Dec 31, 2024−0.7%
Long-term investments200.2M EUR6 Dec 31, 2024

Intangibles and goodwill

ItemLatestA year beforeChange
Goodwill70.0M EUR6 Dec 31, 202469.6M EUR6 Dec 31, 2023+0.7%
Intangible assets, net (excluding goodwill)848.0K EUR6 Dec 31, 2025164.9M EUR6 Dec 31, 2024−99.5%

Inventory

ItemLatestA year beforeChange
Inventory, total22.5M EUR6 Dec 31, 202551.2M EUR6 Dec 31, 2024−56.1%

The story

Founded by Onno van de Stolpe in 1999.1

Galapagos Genomics NV was founded in 1999 as a joint venture between Crucell and Tibotec. The company later changed its name to Galapagos NV and completed its initial public offering on Euronext Amsterdam and Euronext Brussels in May 2005.

The company uses a technological platform for its research, which is based on adenoviruses to introduce human gene sequences into a wide variety of human cell lines to knock-in or knock-down specific proteins.

In 2019, Gilead Sciences and Galapagos entered into transformative research and development collaboration. Gilead and Galapagos have also agreed to amend certain terms around the development and commercialization of filgotinib.

In June 2022, the business announced it would acquire CellPoint for €125 million, with milestones of up to €100 million and AboundBio for $14million.

Effective April 1, 2022 Paul Stoffels replaced cofounder and CEO of 20 years Onno van de Stolpe.

In April 2026 the company was renamed to Lakefront Biotherapeutics.

From Wikipedia’s article on Lakefront Biotherapeutics, shared under CC BY-SA 4.0.8

Leadership

Who has led Galápagos NV, and when. Pick a name to see everywhere that person has worked.

Board members and other officers (1)

Products and brands

  • filgotinib

Listed on Wikidata.1

Subsidiaries and ownership

Subsidiaries

From Wikidata.1

Former names

  • GALAPAGOS NVNov 14, 2007 to May 6, 20267

Timeline

  1. Jul 29, 2010Went public Listed on NASDAQ1
  2. May 6, 2005Went public Listed on Amsterdam Stock Exchange1
  3. 1999Founded Founded1

Filings

202 filings to the SEC since October 2021: 5 annual reports, 17 large holders, 180 other. The latest 20:

  1. Oct 15, 20266-K EDGAR
  2. Oct 13, 20266-K EDGAR
  3. Oct 9, 20266-K EDGAR
  4. Oct 6, 20266-K EDGAR
  5. Sep 29, 20266-K EDGAR
  6. Sep 23, 20266-K EDGAR
  7. Sep 15, 20266-K EDGAR
  8. Sep 8, 20266-K EDGAR
  9. Sep 8, 20266-K EDGAR
  10. Sep 1, 20266-K EDGAR
  11. Aug 25, 20266-K EDGAR
  12. Aug 25, 20266-K EDGAR
  13. Aug 25, 20266-K EDGAR
  14. Aug 18, 20266-K EDGAR
  15. Aug 12, 20266-K EDGAR
  16. Aug 12, 20266-K EDGAR
  17. Aug 4, 20266-K EDGAR
  18. Jul 28, 20266-K EDGAR
  19. Jul 21, 20266-K EDGAR
  20. Jul 15, 20266-K EDGAR

The 202 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 77. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
Gilead Sciences, Inc.16,707,477$500.2M30.3%No change
Tang Capital Management LLC3,785,991$113.5M5.2%No change
Madison Avenue Partners, LP3,447,807$103.4M4.4%+982,628
Prosight Management, LP2,043,344$61.3M10.6%+493,344
EcoR1 Capital, LLC1,667,119$50.0M2.5%No change
Ameriprise Financial Inc1,272,249$38.1M0.0%−152,425
DME Capital Management, LP482,746$14.5M0.4%No change
Renaissance Technologies LLC407,800$12.2M0.0%+92,400
BlackRock, Inc.338,152$10.1M0.0%+26,046
Point72 Asset Management, L.P.269,814$8.1M0.0%−62,311
D. E. Shaw & Co., Inc.197,844$5.9M0.0%−17,874
Millennium Management LLC181,090$5.4M0.0%+73,178
UBS Group AG168,148$5.0M0.0%−7,141
Susquehanna International Group, Llp151,886$4.6M0.0%+138,499
DAFNA Capital Management LLC130,175$3.9M0.7%No change
Citadel Advisors LLC88,343$2.6M0.0%−36,085
Two Sigma Investments, LP81,749$2.5M0.0%+55,889
Norges Bank76,879$2.3M0.0%New
Alps Advisors Inc65,523$2.0M0.0%+11,862
Goldman Sachs Group Inc56,581$1.7M0.0%+11,210
American Century Companies Inc40,804$1.2M0.0%+2,014
Barometer Capital Management Inc.40,800$1.2M0.3%+2,700
Morgan Stanley37,682$1.1M0.0%+11,063
Schonfeld Strategic Advisors LLC32,597$977.3K0.0%New
Marshall Wace, Llp32,399$971.3K0.0%New

13F reports cover disclosed long positions in U.S. stocks only.

SEC filer profile

How Galápagos NV is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARLakefront Biotherapeutics NV2
  • CIK0001421876
  • Filer statusLarge accelerated filer not an emerging growth company; not a shell company23
  • Incorporated inBelgium23
  • Industry code (SIC)2834 Pharmaceutical Preparations2
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance2
  • Business addressSchalienhoevedreef 20T, 2800 Mechelen, Belgium2
  • Phone32153429002
  • Shares outstanding65,897,071 shares as of Dec 31, 202523
  • AuditorBDO Bedrijfsrevisoren BV, Zaventem, Belgium PCAOB ID 1432; it also attests to the company’s internal control over financial reporting23
  • On EDGAR sinceNov 14, 20072
  • Filings542 in all: 6-K (433), SC 13G/A (20), S-8 (13), 20-F (11), SC 13G (10), F-1/A (5), UPLOAD (5), 424B5 (4)2
    All 30 form types

    CORRESP (4), SC 13D/A (4), CT ORDER (3), EFFECT (3), SC 13D (3), SCHEDULE 13D/A (3), 424B3 (2), DRS/A (2), F-3ASR (2), F-6 (2), SCHEDULE 13G (2), 12G3-2B (1), 424B4 (1), 8-A12B (1), ARS (1), CERTNAS (1), DRS (1), F-1 (1), F-1MEF (1), FWP (1), SCHEDULE 13D (1), SUPPL (1)

  • Latest filingsAnnual report (20-F) Mar 26, 2026

Securities registered for trading

ClassSymbolExchange
American Depositary Shares, each representing oneGLPGNasdaq

From the cover page of the 20-F filed Mar 26, 2026 (Section 12(b) of the Exchange Act).23

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23